Integra LifeSciences (NASDAQ:IART) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Integra LifeSciences (NASDAQ:IART) posted its quarterly earnings data on Monday. The life sciences company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.39 by $0.02, Briefing.com reports. The company had revenue of $380.80 million during the quarter, compared to analyst estimates of $375.81 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.25%. Integra LifeSciences’s quarterly revenue was down .4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.76 earnings per share.

Integra LifeSciences Stock Up 7.2 %

Integra LifeSciences stock opened at $26.70 on Thursday. The business’s 50-day simple moving average is $18.90 and its two-hundred day simple moving average is $24.40. The company has a debt-to-equity ratio of 1.17, a quick ratio of 2.10 and a current ratio of 3.39. The company has a market cap of $2.07 billion, a PE ratio of -296.67, a PEG ratio of 0.82 and a beta of 1.08. Integra LifeSciences has a fifty-two week low of $16.81 and a fifty-two week high of $45.42.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Citigroup raised their price target on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research note on Tuesday. Truist Financial reduced their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a report on Monday, October 14th. Bank of America dropped their price objective on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a research note on Monday, October 7th. Morgan Stanley lifted their price objective on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a report on Monday, July 15th. Finally, BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $27.25.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.